Total Clarity Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Total Clarity Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-74	Closed	-$4K	–	361
2022 Q2	$4K	Buy	+74	New	+$4.35K	﹤0.01%	837
2022 Q1	–	Sell	-360	Closed	-$27K	–	347
2021 Q4	$27K	Sell	360 -150	-29%	-$13.1K	0.01%	508
2021 Q3	$57K	Buy	+510	New	+$64.1K	0.03%	381
2021 Q2	–	Sell	-260	Closed	-$32K	–	298
2021 Q1	$32K	Buy	+260	New	+$39.3K	0.02%	387
2020 Q1	–	Sell	-100	Closed	-$6K	–	191
2019 Q4	$6K	Buy	+100	New	+$5.46K	﹤0.01%	556

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Total Clarity Wealth Management's CRSP Position: Q3 2022 in Review

Total Clarity Wealth Management sold out of CRISPR Therapeutics (CRSP) in Q3 2022, closing a stake of 74 shares — an estimated $4K sold.

Total Clarity Wealth Management first reported a position in CRSP in Q4 2019 and held it in 5 quarters. The position peaked at $57K in Q3 2021. 436 funds tracked by Wall St. Rank hold CRSP as of Q3 2022.

Total Clarity Wealth Management reported no remaining CRISPR Therapeutics position as of Q3 2022 after selling out during the quarter.
Total Clarity Wealth Management sold 74 CRISPR Therapeutics shares in Q3 2022, an estimated $4K.
Total Clarity Wealth Management first reported a position in CRISPR Therapeutics in Q4 2019 and held it in 5 quarters.
Total Clarity Wealth Management's CRISPR Therapeutics position peaked at $57K in Q3 2021.
436 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2022.

Based on Total Clarity Wealth Management's 13F filing for Q3 2022, filed 4 Nov 2022.